Commentary: tegaserod and IBS, two decades on
- PMID: 31850554
- DOI: 10.1111/apt.15516
Commentary: tegaserod and IBS, two decades on
Comment on
-
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.Aliment Pharmacol Ther. 2001 Oct;15(10):1655-66. doi: 10.1046/j.1365-2036.2001.01094.x. Aliment Pharmacol Ther. 2001. PMID: 11564007 Clinical Trial.
References
REFERENCES
-
- Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666.
-
- FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document. https://www.fda.gov/media/119013/download. Accessed August 19, 2019.
-
- Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... Accessed September 1, 2019.
-
- Guidance for Industry Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. https://www.fda.gov/media/78622/download. Accessed September 2, 2019.